1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. METAGENOMICS MARKET BY TYPE
5.1. Introduction
5.2. Targeted Sequencing
5.3. Shot-Gun Sequencing
6. METAGENOMICS MARKET BY APPLICATION
6.1. Introduction
6.2. Disease Diagnostics
6.3. Vaccine Development
6.4. Drug Discovery
6.5. Others
7. METAGENOMICS MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Academic & Research Institutes
7.4. Others
8. METAGENOMICS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Bio-Rad Laboratories Inc.
10.2. Illumina, Inc.
10.3. Thermo Fisher Scientific, Inc.
10.4. Novogene Co., Ltd.
10.5. QIAGEN
10.6. Takara Bio, Inc.
10.7. Oxford Nanopore Technologies plc
10.8. F. Hoffmann-La Roche Ltd.
10.9. Eurofins Scientific SE
10.10. BGI Group
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES